Sentences with phrase «tumor immunology»
"Tumor immunology" refers to the study of how our immune system detects and fights against cancer cells. It explores how the immune system recognizes tumor cells as foreign and tries to destroy them in order to protect our body. Full definition
She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 for her contributions to the discovery of PD - 1 pathway.
warrenalpert.org
Concise review: Humanized models of tumor immunology in the 21st century: Convergence of cancer research and tissue engineering.
«Our data provide proof of concept that DMAb engineered DNA plasmids can be successfully used to target important cancers,» said Kar Muthumani, M.Sc., Ph.D., assistant professor in the Translational Tumor Immunology Program at Wistar, member of the Vaccine & Immunotherapy Center and lead author of the study.
«Studies pointed to STAT3 being an important target in the development of cancer,» said Dmitry I. Gabrilovich, M.D., Ph.D., the Christopher M. Davis Professor and Professor and Program Leader in the Translational Tumor Immunology Program at The Wistar Institute and lead author of the study.
The project associates the expertise of IRIBHM in GPCR discovery and validation, the unique technology on sensory GPCRs developed by ChemCom, the in - depth tumor immunology expertise of de Duve with the drug discovery capabilities of iTeos and the expertise of ImmunXperts with human primary cells in immuno - oncology.
Several research groups of the Institute focus on tumor immunology and cancer immunotherapy.
For a while, people were not keen on anyone who wanted to do tumor immunology.
After graduating from Johns Hopkins Medical School, he trained in internal medicine at John's Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana - Farber Cancer Institute.
She trained in tumor immunology as a senior clinical and research fellow before joining the faculty at Johns Hopkins University in 2001.
The IT - Targets project provides a unique opportunity to explore the roles of G protein - coupled receptors in human tumor immunology.
Fascinated by the concept of cancer vaccines, I undertook my PhD in tumor immunology jointly at the University of Southampton (Ottensmeier Lab) and University of California, San Francisco (Coussens Lab).
About the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology CRI established this award in 1975 in honor of Dr. William B. Coley, a pioneer of cancer immunotherapy, whose daughter Helen Coley Nauts (1907 - 2001) founded the Cancer Research Institute.
CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.
«That's when Big Pharma started sniffing around and really got interested in immunotherapy,» says Jeffrey Schlom, chief of the National Cancer Institute's Laboratory of Tumor Immunology and Biology.
Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center
An open access, peer - reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
They said, «Why are you going to do tumor immunology?
He received the William B. Coley Award for Distinguished Research in Tumor Immunology in 2014 and the Laguna Biotech CEO Forum award for his contributions to the discovery of the PD - 1 pathway.
With standard clinical trials, the criteria used to confirm benefit do not apply to vaccines, points out Jeffrey Schlom, chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.
The reasons are under investigation, but the 408 patients in the study had the most advanced prostate cancer possible, «exactly the patient population for which [one] would not use a vaccine,» remarks Jeffrey Schlom, chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.
«What he showed us is turning the immune system on isn't enough; the crucial step is to make sure it doesn't turn itself off,» says Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center.
He is also a member and co-leader of the Tumor Immunology Focus Panel for the NCI - designated Knight Cancer Institute and adjunct faculty member, Department of Molecular Microbiology and Immunology, Oregon Health and Science University.
He is the Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.
He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2017 Warren Alpert Foundation award for this work, which led to development of the PD - 1 pathway blockade for cancer immunotherapy.
Dr. Sadelain is the recipient of the Cancer Research Institute's William B. Coley Award for Distinguished Research in Tumor Immunology, the Sultan Bin Khalifa International Award for Innovative Medical Research on Thalassemia, and the New York Intellectual Property Law Association Inventor of the Year Award.
He actively participates in the Host - Tumor Interactions and Tumor Immunology programs.
Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.
Research Interests: tumor immunology; suppressor cells; immune evasion; oncogenes; chemotherapy resistance
Applications were reviewed by CRI's Postdoctoral Fellowship Review Committee, which twice annually vets highly competitive applications from young scientists working in top immunology and tumor immunology laboratories around the world.
The Clinical Accelerator, building on 60 + years of CRI's dedication to funding the most innovative basic science in tumor immunology, enables experts to advance their most ambitious clinical and translational research ideas to cure cancer, and accelerates studies that one group or company could not do alone.
The Clinical Accelerator network includes approximately 80 of the world's leading physician - scientists with expertise in tumor immunology and cancer immunotherapy clinical trials, immune monitoring, and correlative research.
At the dinner, the Cancer Research Institute will also celebrate excellence in scientific research with presentations of the 2017 William B. Coley Award for Distinguished Research in Basic Immunology to Rafi Ahmed, Ph.D., of Emory University, and the 2017 William B. Coley Award for Distinguished Research in Tumor Immunology to Thomas F. Gajewski, M.D., Ph.D., of the University of Chicago.
He has research experience in Rheumatology, Tumor Immunology and Salmonellosis / Typhoid Fever.
Gosselies, Belgium — February 10, 2017 — iTeos Therapeutics SA, a Belgian privately - held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos» Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.
Michel Detheux, iTeos» Chief Executive Officer added, «The progress of our adenosine A2A antagonist program demonstrates how we can rapidly apply our expertise in medicinal chemistry, tumor immunology and translational medicine to advance candidates toward clinical development.»
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept..
Gosselies, Belgium — November 28, 2016 — iTeos, a biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, announced today that it has completed the relocation of its 39 employees into a newly rebuilt, 1,500 square meter (16,200 square foot) corporate headquarters which now houses iTeos» offices and laboratories.
Although he had never conducted research in tumor immunology, in 1979 Steinman submitted an application to the Cancer Research Institute for a pilot grant to explore this novel hypothesis.
iTeos» competitive edge is in the combination of expertise in drug discovery and translational tumor immunology.
Fascinated by human immunology and translational research, I undertook my PhD in tumor immunology at the University of Tuebingen (Germany).
Bryan Choi, the recipient of a Student Training and Research in Tumor Immunology (STaRT) grant at Duke University, is working to develop a new strategy using Bispecific T cell Engagers (BiTEs) to treat glioblastoma.
iTeos Therapeutics is leveraging its expertise in tumor immunology, translational medicine and drug discovery to deliver the next wave of immune therapies for the treatment of inflamed (hot) and non-inflamed (cold) tumors.